NOV 05, 2017 09:15 AM PST

New Drug 'Transformed' Infant Patients With Deadly Disorder

WRITTEN BY: Carmen Leitch

Spinal muscular atrophy (SMA) type 1 is a debilitating genetic disease impacting muscle development in infants. A new drug significantly improved symptoms in those patients; when treated, they were more likely to show improvement in motor function, and they were 47 percent more likely to live without needing a ventilator. The drug was so beneficial to patients in the study that it was halted early, and nusinersen was approved by the Food & Drug Administration for any individual with this disease. The results were reported in the New England Journal of Medicine and are outlined in the following video. 

"This is transformative for children with SMA," commented the lead author of the study, Richard S. Finkel, M.D., the Chief of Neurology at Nemours Children's Hospital in Orlando. "Babies with this debilitating and deadly disease were destined to have a short lifespan and limited motor function. This study shows nusinersen is life-altering for families touched by this genetic disorder."

SMA impacts around one in 11,000 births, with about 60 percent of cases being the severe type 1; milder cases occur in children and adults. Around one in 40 adults carry the mutation that causes the disease. The severe neuromuscular disorder starts any time before six months of age and causes progressive weakness in muscles. Affected infants are never able to sit up and have trouble breathing and swallowing, causing lung infections. Most of these infants don’t survive to their second birthday unless they have a feeding tube or other help from devices.  

Nusinersen is the first treatment option for SMA and acts on the SMN2 gene. A small piece of synthetic DNA, an antisense oligonucleotide (ASO) is injected into the spinal fluid directly, where spinal nerve cells absorb it. The ASO results in an increase in the synthesis of a protein that is needed for neuromotor development.

This study assessed 121 infants with SMA Type 1 who came from 31 centers in thirteen countries. Because both physicians and family members did not know whether a patient received the drug, it was a double-blind, randomized study. The researchers developed special procedures to ensure researchers interacting with patients did not know who had gotten medication through a spinal injection.

Infants with SMA type 1 showed improvement after drug treatment. / Image credit: Pixabay

Over the course of thirteen months, 41 percent of the infants treated with nusinersen showed improvement in motor function, and several began to develop motor skills like sitting, standing, kicking, head control, and rolling over. No progress was seen in untreated infants in the control group. In nusinersen-treated infants, the risk of death was 63 percent lower, and they were less likely to need permanent ventilation assistance. There were not any serious patient problems after administration of the drug, which was well-tolerated.

The FDA approved nusinersen, sold as Spinraza, after checking the interim data from the study in December 2016. After the study ended, another one began to evaluate the long-term effects of the drug on these patients. It is also being tested in individuals with milder forms of the disease as well as infants found to have it through genetic testing, but who do not yet display symptoms. There is an effort by Dr. Finkel and colleagues to add SMA to a newborn screening panel so it can be diagnosed and treated immediately.


Sources: AAAS/Eurekalert! Via Nemours Children’s Health System, NEJM

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
OCT 18, 2019
Cell & Molecular Biology
OCT 18, 2019
Stopping Metastasis After Breast Cancer Surgery
Cancer is most deadly when it metastasizes, which can happen after tumor-removal surgery. It's a serious challenge for many patients....
OCT 18, 2019
Microbiology
OCT 18, 2019
The Long Evolutionary History of Antibiotics and Resistance
The world is full of bacteria that have to share the world with myriad species, and often have to live in competition with other microbes....
OCT 18, 2019
Genetics & Genomics
OCT 18, 2019
Do You Inherit Your Morals?
Morality is usually a subject discussed by philosophers, not biologists. But is it really a purely philosophical issues? After all, what makes us more susc...
OCT 18, 2019
Cell & Molecular Biology
OCT 18, 2019
Investigating the Formation of Membrane-less Organelles
The cytoplasm of cells is about 80% water, but is full of a molecular mixture of stuff that was once thought to be disorganized and random....
OCT 18, 2019
Cell & Molecular Biology
OCT 18, 2019
Insight Into the Epigenetic Mechanisms Controlling Cellular Identity
Every cell type has to carefully control which genes are expressed, and new research has learned more about that process....
OCT 18, 2019
Cell & Molecular Biology
OCT 18, 2019
Watching Neurons Form the First Circuits in a Developing Embryo
As an organism develops, it has to form the right types of cells, like heart or muscle or nerve cells, and then move them into the correct places....
Loading Comments...